Skip to Main Content
  • Become an Access Reviewer
  • Clinical Phenotypes
  • OMMBID Advisory banner
  • Ommbid banner
  • Ommbid latest banner



  1. The activated form of factor IX (F.IXa), a vitamin K-dependent protein made exclusively in the liver, is an enzyme required for amplification in the series of reactions leading to blood clot formation. Factor IX deficiency (hemophilia B or Christmas disease) results in a bleeding disorder, phenotypically identical to the more common Hemophilia A, which results from a deficiency of factor VIII.

  2. Clinically, the disease exists in severe (F.IX levels <1 percent normal), moderate (1 to 5 percent), and mild (6 to 30 percent) forms. The major symptom of the disease is spontaneous bleeding into joints and soft tissues. Bleeding at others sites is less common but can be life or limb threatening; for example, intracranial or compartmental syndrome bleeding.

  3. A detailed and extensive database of mutations resulting in hemophilia B that includes more than 1918 patient entries as of mid 2000 ( provides information about all known mutations.

  4. Treatment options include replacement of the missing protein with purified or recombinant F.IX protein and most recently gene therapy. Complications of treatment include thrombogenicity, blood-borne viral diseases, and the development of an inhibitory F.IX antibody. The presence of an anti-F.IX inhibitory antibody is clinically problematic and treated acutely by delivery of proteins (recombinant Factor VIIa) that bypass the requirement for F.IX. In addition, initiation of immune tolerance regimens (daily injection of high doses of F.IX) is designed to eradicate the inhibitory antibody.

  5. Murine and canine models of hemophilia B facilitate testing of novel therapies such as gene therapy.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

OMMBID Full Site: One-Year Subscription

Connect to the full suite of OMMBID content including new and revised chapters that reflect the latest research, image galleries, clinical phenotypes, and more.

$295 USD
Buy Now

Pay Per View: Timed Access to all of OMMBID

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.